Summary:
To establish incidence and risk factors for development of second malignant neoplasms after high-dose chemo/radiotherapy (HDT) and autologous hematopoietic stem cell transplantation (AHSCT), the case files of 800 consecutive patients who underwent AHSCT at our institution between June 1982 and December 2000 were reviewed. In all, 26 patients developed 29 second malignancies (nine myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML), 16 solid tumors and four lymphoproliferative disorders (LPDs)) for a 15-year cumulative incidence of 11% (95% confidence interval (CI), 5–18%). These second tumors occurred at a median of 68 (range 1.5–177) months following AHSCT. The relative risk (RR) compared to the general population of developing a second malignancy following AHSCT was 3.3 (CI 2.2–4.7) P<0.001. The RR of developing MDS/AML, LPD and a solid tumor was 47.2 (CI 21.5–89.5) P<0.001, 8.1 (2.2–20.7) P=0.002 and 1.98 (1.1–3.2) P=0.009, respectively. In multivariate analysis, age ⩾35 years at the time of AHSCT (P=0.001) and an interval from diagnosis to AHSCT ⩾36 months (P=0.03) were associated with a greater risk of developing a second malignancy. Patients who have undergone HDT and AHSCT are at significant risk for developing a second malignancy and should receive indefinite follow-up.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Clift RA, Appelbaum FR, Thomas ED . Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82: 1954–1956.
Cassileth PA, Harrington DP, Appelbaum FR et al. Chemo-therapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649–1700.
Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132–1143.
Reece DE, Connors JM, Spinelli JJ et al. Intensive therapy with cyclophosphamide, carmustine, etoposide±cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83: 1193–1199.
Barnett MJ, Coppin CML, Murray N et al. High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumours. Br J Cancer 1993; 68: 594–598.
Kolb HJ, Bender-Gotze C . Late complications after allogeneic bone marrow transplantation for leukaemia. Bone Marrow Transplant 1990; 6: 61–72.
Baker KS, DeFor TE, Burns LJ et al. New malignancies after blood or marrow stem cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352–1358.
Curtis RE, Rowlings PA, Deeg HJ et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897–904.
Socie G, Henry-Amar M, Cosset JM et al. Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood 1991; 78: 277–279.
Witherspoon RP, Deeg HJ, Storb R . Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. Transplantation 1994; 57: 1413–1418.
Deeg HJ, Socie G, Schoch G et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87: 386–392.
Bhatia S, Ramsay NKC, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633–3639.
Deeg HJ, Socie G . Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998; 91: 1833–1844.
Chao NJ, Nademanee AP, Long GD et al. Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease. J Clin Oncol 1991; 9: 1575–1579.
Miller JS, Arthur DC, Litz CE et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 1994; 83: 3780–3786.
Traweek ST, Slovak ML, Nademanee AP et al. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood 1994; 84: 957–963.
Stone RM, Neuberg D, Soiffer R et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2535–2542.
Darrington DL, Vose JM, Anderson JR et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemo-radiotherapy and autologous stem cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12: 2527–2534.
Metayer C, Curtis RE, Vose J et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case–control study. Blood 2003; 101: 2015–2023.
Milligan DW, Ruiz de Elvira MC, Kolb H-J et al. Secondary leukaemia and myelodysplasia after autografting for lymph-oma: results from the EBMT. Br J Haematol 1999; 106: 1020–1026.
Pedersen-Bjergaard J . Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review. Leukemia Res 1992; 16: 61–65.
Sobecks RM, Le Beau MM, Anastasi J, Williams SF . Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23: 1161–1165.
Abruzzese E, Radford JE, Miller JS et al. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood 1999; 94: 1814–1819.
André M, Henry-Amar M, Blaise D et al. Treatment-related deaths and second cancer risk after autologous stem cell transplantation for Hodgkin's disease. Blood 1998; 92: 1933–1940.
Yeager AM, Kaizer H, Santos GW et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydro-peroxycyclophosphamide. N Engl J Med 1986; 315: 141–147.
Gorin NC, Labopin M, Meloni G et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. Leukemia 1991; 5: 896–904.
Klingemann H-G, Eaves CJ, Barnett MJ et al. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 1994; 14: 389–396.
Barnett MJ, Eaves CJ, Phillips GL et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 1994; 84: 724–732.
Kalbfleisch JD, Prentice RL . The Statistical Analysis of Failure Time Data. John Wiley & Sons: New York, 1998.
Cox DR . Regression models and life tables. J R Stat Soc Ser B 1972; 34: 187–220.
Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
Toze CL, Barnett MJ, Klingemann H-G . Response of therapy-related myelodysplasia to low-dose interleukin-2. Leukemia 1993; 7: 463–465.
Shepherd JD, Gascoyne RD, Barnett MJ et al. Polyclonal Epstein–Barr virus-associated lymphoproliferative disorder following autografting for chronic myeloid leukemia. Bone Marrow Transplant 1995; 15: 639–641.
Lohrisch CA, Nevill TJ, Barnett MJ et al. Development of a biologically distinct EBV-related lymphoproliferative disorder following autologous bone marrow transplantation for an EBV-negative post-renal allograft Burkitt's lymphoma. Leukemia Lymphoma 2000; 39: 195–201.
Tong MJ, El-Farra NS, Reikes AR, Co RL . Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463–1466.
Lee YS, Kim IG . Radiation-induced tumorigenesis. J Biochem Mol Biol 2003; 36: 144–148.
Ng AK, Bernardo MVP, Weller E et al. Second malignancy after Hodgkin's disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100: 1989–1996.
Nalesnik MA . Clinicopathologic features of post transplant lymphoproliferative disorders. Ann Transplant 1997; 2: 33–40.
Friedberg JW, Neuberg D, Stone RM et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3128–3135.
Micallef INM, Lillington DM, Apostolidis J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: 947–955.
Orchard JA, Bolam S, Oscier DG . Association of myelo-dysplastic changes with purine analogues. Br J Haematol 1998; 100: 677–679.
Krishnan A, Bhatia S, Slovak ML et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588–1593.
Ershler WB, Longo DL . Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst 1997; 89: 1489–1497.
Josting A, Wiedenmann S, Franklin J et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2000.
Armitage JO, Carbone PP, Connors JM et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003; 21: 897–906.
Pui CH, Ribeiro RC, Hancock ML et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325: 1682–1687.
Bhatia S, Sather HN, Pabustan OB et al. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood 2002; 99: 4257–4264.
Neglia JP, Meadows AT, Robison LL et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 325: 1330–1336.
Duker NJ . Chromosome breakage syndromes and cancer. Am J Med Genet 2002; 115: 125–129.
van den Akker J, Gorin NC, Laporte JP et al. Chromosome abnormalities after autologous bone marrow transplantation with marrow treated by cyclophosphamide derivatives. Lancet 1985; 1: 1211–1222.
Perot C, van den Akker J, Laporte JP et al. Chromosome abnormalities in patients with acute leukemia after autologous bone marrow transplantation using total body irradiation and marrow purged with mafosfamide. Leukemia 1993; 7: 509–515.
Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85–86.
Acknowledgements
We wish to acknowledge the contribution of the medical and nursing staff of East 6 Ward and BMT Daycare at the Vancouver General Hospital, the staff of 6 West Ward at the British Columbia Cancer Agency, the staff of 3B Ward at the British Columbia's Children's Hospital, and Ms Louise Myers for preparation of the manuscript and tables.
Author information
Authors and Affiliations
Corresponding author
Additional information
The Leukemia and Bone Marrow Transplantation Program of British Columbia
Rights and permissions
About this article
Cite this article
Forrest, D., Nevill, T., Naiman, S. et al. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis. Bone Marrow Transplant 32, 915–923 (2003). https://doi.org/10.1038/sj.bmt.1704243
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704243
Keywords
This article is cited by
-
Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors
Annals of Hematology (2023)
-
Twenty years of experience of a tertiary cancer center in total body irradiation with focus on oncological outcome and secondary malignancies
Strahlentherapie und Onkologie (2022)
-
Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry
Bone Marrow Transplantation (2018)
-
Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters
Bone Marrow Transplantation (2016)
-
Tissue engineering and regenerative medicine in musculoskeletal oncology
Cancer and Metastasis Reviews (2016)